BRAF and neoplasm: If the intensity of antitumor treatment plays a role in the evolution of mCRC—based on our observations—it should be questioned if the clinical challenge of treating BRAF-MT mCRC is best addressed by maximizing initial efficacy or by applying a sequential therapy that might induce less tumor response but is possibly associated with less aggressive tumor evolution in the course of disease.